Insilico Medicine CEO Alex Zhavoronkov on AI in Longevity Therapeutics at ARDD 2026
Alex Zhavoronkov, CEO of Insilico Medicine, presented at ARDD 2026 on using AI to discover and develop longevity therapeutics credibly and equitably.
ImportanceLocalPreuvesE2 non réplicableTraitementRapide
This video resource features a presentation by Alex Zhavoronkov, CEO and Chief Business Officer of Insilico Medicine, at the ARDD 2026 conference. Zhavoronkov is a recognized figure in AI-driven drug discovery, leading a company focused on accelerating new drug development through artificial intelligence.
The talk is titled 'Longevity Therapeutics as the Most Impactful Trillion-Dollar Industry in Biotechnology: How to Discover and Develop Them in the Most Credible and Equitable Way with AI.' The topic centers on the potential of AI technology to address complex biomedical challenges, particularly in the frontier field of longevity.
For readers interested in the practical application of AI in biopharmaceuticals, this presentation offers a macro perspective from an industry leader on technical pathways and industrial prospects. Although a full transcript is not provided, the speaker's authority and the relevance of the topic make this resource worth selecting.